Loading…

Reprogramming autologous skeletal myoblasts to express cardiomyogenic function. Challenges and possible approaches

Cell transplantation therapy is emerging as a promising mode of treatment following myocardial infarction. Of the various cell types that can potentially be used for transplantation, autologous skeletal myoblasts appear particularly attractive, because this would avoid issues of immunogenicity, tumo...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cardiology 2005-04, Vol.100 (3), p.355-362
Main Authors: Heng, Boon Chin, Khawaja Haider, Husnain, Kwang-Wei Sim, Eugene, Cao, Tong, Qing Tong, Guo, Chye Ng, Soon
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c390t-89c725602b7e1bb8d41e2d2d6399716d319381aa8916ce1e1ba19fb4e795ca63
cites cdi_FETCH-LOGICAL-c390t-89c725602b7e1bb8d41e2d2d6399716d319381aa8916ce1e1ba19fb4e795ca63
container_end_page 362
container_issue 3
container_start_page 355
container_title International journal of cardiology
container_volume 100
creator Heng, Boon Chin
Khawaja Haider, Husnain
Kwang-Wei Sim, Eugene
Cao, Tong
Qing Tong, Guo
Chye Ng, Soon
description Cell transplantation therapy is emerging as a promising mode of treatment following myocardial infarction. Of the various cell types that can potentially be used for transplantation, autologous skeletal myoblasts appear particularly attractive, because this would avoid issues of immunogenicity, tumorigenesis, ethics and donor availability. Additionally, skeletal myoblasts display much higher levels of ischemic tolerance and graft survival compared to other cell types. There is some evidence for improvement in heart function with skeletal myoblast transplantation. However, histological analysis revealed that transplanted myoblasts do not transdifferentiate into functional cardiomyocytes in situ. This is evident by the lack of expression of cardiac-specific antigens, and the absence of intercalated disc formation. Instead, there is differentiation into myotubes that are not electromechanically coupled to neighboring cardiomyocytes. This could in turn limit the clinical efficacy of treatment. This review would therefore examine the various challenges faced in attempting to reprogram autologous skeletal myoblast to express cardiomyogenic function, together with the various possible strategies that could be employed to achieve this objective.
doi_str_mv 10.1016/j.ijcard.2004.06.009
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67814672</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167527304006886</els_id><sourcerecordid>67814672</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-89c725602b7e1bb8d41e2d2d6399716d319381aa8916ce1e1ba19fb4e795ca63</originalsourceid><addsrcrecordid>eNp9kE1r3DAQhkVoaTZJ_0EourQ3u5I_JOtSKEvbFAKFkrsYS2NHW9lyJbsk_z5adiG3nnTQM-878xByy1nJGRefD6U7GIi2rBhrSiZKxtQF2fFONgWXbfOG7DImi7aS9SW5SunAMqhU945c8rbrGq7YjsTfuMQwRpgmN48UtjX4MIYt0fQHPa7g6fQceg9pTXQNFJ-WiCnRY7ML-WvE2Rk6bLNZXZhLun8E73EeMVGYLV1CSq73SGHJPWAeMd2QtwP4hO_P7zV5-P7tYX9X3P_68XP_9b4wtWJr0Skjq1awqpfI-76zDcfKVlbUSkkubM1V3XGATnFhkGcGuBr6BqVqDYj6mnw6xebevxumVU8uGfQeZsz3aSE73ghZZbA5gSbmZSMOeolugvisOdNH1fqgT6r1UbVmQmfVeezDOX_rJ7SvQ2e3Gfh4BiAZ8EOE2bj0yuVuXqlj0JcTh1nGP4dRJ-NwNmhdRLNqG9z_N3kBxNGhRw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67814672</pqid></control><display><type>article</type><title>Reprogramming autologous skeletal myoblasts to express cardiomyogenic function. Challenges and possible approaches</title><source>Elsevier</source><creator>Heng, Boon Chin ; Khawaja Haider, Husnain ; Kwang-Wei Sim, Eugene ; Cao, Tong ; Qing Tong, Guo ; Chye Ng, Soon</creator><creatorcontrib>Heng, Boon Chin ; Khawaja Haider, Husnain ; Kwang-Wei Sim, Eugene ; Cao, Tong ; Qing Tong, Guo ; Chye Ng, Soon</creatorcontrib><description>Cell transplantation therapy is emerging as a promising mode of treatment following myocardial infarction. Of the various cell types that can potentially be used for transplantation, autologous skeletal myoblasts appear particularly attractive, because this would avoid issues of immunogenicity, tumorigenesis, ethics and donor availability. Additionally, skeletal myoblasts display much higher levels of ischemic tolerance and graft survival compared to other cell types. There is some evidence for improvement in heart function with skeletal myoblast transplantation. However, histological analysis revealed that transplanted myoblasts do not transdifferentiate into functional cardiomyocytes in situ. This is evident by the lack of expression of cardiac-specific antigens, and the absence of intercalated disc formation. Instead, there is differentiation into myotubes that are not electromechanically coupled to neighboring cardiomyocytes. This could in turn limit the clinical efficacy of treatment. This review would therefore examine the various challenges faced in attempting to reprogram autologous skeletal myoblast to express cardiomyogenic function, together with the various possible strategies that could be employed to achieve this objective.</description><identifier>ISSN: 0167-5273</identifier><identifier>EISSN: 1874-1754</identifier><identifier>DOI: 10.1016/j.ijcard.2004.06.009</identifier><identifier>PMID: 15884190</identifier><identifier>CODEN: IJCDD5</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Biological and medical sciences ; Cardiology. Vascular system ; Cardiomyocytes ; Cell Differentiation - physiology ; Cells, Cultured ; Coronary heart disease ; Heart ; Heart Failure - physiopathology ; Humans ; Medical sciences ; Myoblasts, Skeletal - metabolism ; Myoblasts, Skeletal - transplantation ; Myocardial ischemia ; Myocarditis. Cardiomyopathies ; Myocytes, Cardiac - physiology ; Recovery of Function ; Skeletal myoblasts ; Transcription Factors - physiology ; Transdifferentiation ; Transplantation ; Transplantation, Autologous</subject><ispartof>International journal of cardiology, 2005-04, Vol.100 (3), p.355-362</ispartof><rights>2004 Elsevier Ireland Ltd</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-89c725602b7e1bb8d41e2d2d6399716d319381aa8916ce1e1ba19fb4e795ca63</citedby><cites>FETCH-LOGICAL-c390t-89c725602b7e1bb8d41e2d2d6399716d319381aa8916ce1e1ba19fb4e795ca63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=16721299$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15884190$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Heng, Boon Chin</creatorcontrib><creatorcontrib>Khawaja Haider, Husnain</creatorcontrib><creatorcontrib>Kwang-Wei Sim, Eugene</creatorcontrib><creatorcontrib>Cao, Tong</creatorcontrib><creatorcontrib>Qing Tong, Guo</creatorcontrib><creatorcontrib>Chye Ng, Soon</creatorcontrib><title>Reprogramming autologous skeletal myoblasts to express cardiomyogenic function. Challenges and possible approaches</title><title>International journal of cardiology</title><addtitle>Int J Cardiol</addtitle><description>Cell transplantation therapy is emerging as a promising mode of treatment following myocardial infarction. Of the various cell types that can potentially be used for transplantation, autologous skeletal myoblasts appear particularly attractive, because this would avoid issues of immunogenicity, tumorigenesis, ethics and donor availability. Additionally, skeletal myoblasts display much higher levels of ischemic tolerance and graft survival compared to other cell types. There is some evidence for improvement in heart function with skeletal myoblast transplantation. However, histological analysis revealed that transplanted myoblasts do not transdifferentiate into functional cardiomyocytes in situ. This is evident by the lack of expression of cardiac-specific antigens, and the absence of intercalated disc formation. Instead, there is differentiation into myotubes that are not electromechanically coupled to neighboring cardiomyocytes. This could in turn limit the clinical efficacy of treatment. This review would therefore examine the various challenges faced in attempting to reprogram autologous skeletal myoblast to express cardiomyogenic function, together with the various possible strategies that could be employed to achieve this objective.</description><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Cardiomyocytes</subject><subject>Cell Differentiation - physiology</subject><subject>Cells, Cultured</subject><subject>Coronary heart disease</subject><subject>Heart</subject><subject>Heart Failure - physiopathology</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Myoblasts, Skeletal - metabolism</subject><subject>Myoblasts, Skeletal - transplantation</subject><subject>Myocardial ischemia</subject><subject>Myocarditis. Cardiomyopathies</subject><subject>Myocytes, Cardiac - physiology</subject><subject>Recovery of Function</subject><subject>Skeletal myoblasts</subject><subject>Transcription Factors - physiology</subject><subject>Transdifferentiation</subject><subject>Transplantation</subject><subject>Transplantation, Autologous</subject><issn>0167-5273</issn><issn>1874-1754</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNp9kE1r3DAQhkVoaTZJ_0EourQ3u5I_JOtSKEvbFAKFkrsYS2NHW9lyJbsk_z5adiG3nnTQM-878xByy1nJGRefD6U7GIi2rBhrSiZKxtQF2fFONgWXbfOG7DImi7aS9SW5SunAMqhU945c8rbrGq7YjsTfuMQwRpgmN48UtjX4MIYt0fQHPa7g6fQceg9pTXQNFJ-WiCnRY7ML-WvE2Rk6bLNZXZhLun8E73EeMVGYLV1CSq73SGHJPWAeMd2QtwP4hO_P7zV5-P7tYX9X3P_68XP_9b4wtWJr0Skjq1awqpfI-76zDcfKVlbUSkkubM1V3XGATnFhkGcGuBr6BqVqDYj6mnw6xebevxumVU8uGfQeZsz3aSE73ghZZbA5gSbmZSMOeolugvisOdNH1fqgT6r1UbVmQmfVeezDOX_rJ7SvQ2e3Gfh4BiAZ8EOE2bj0yuVuXqlj0JcTh1nGP4dRJ-NwNmhdRLNqG9z_N3kBxNGhRw</recordid><startdate>20050428</startdate><enddate>20050428</enddate><creator>Heng, Boon Chin</creator><creator>Khawaja Haider, Husnain</creator><creator>Kwang-Wei Sim, Eugene</creator><creator>Cao, Tong</creator><creator>Qing Tong, Guo</creator><creator>Chye Ng, Soon</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20050428</creationdate><title>Reprogramming autologous skeletal myoblasts to express cardiomyogenic function. Challenges and possible approaches</title><author>Heng, Boon Chin ; Khawaja Haider, Husnain ; Kwang-Wei Sim, Eugene ; Cao, Tong ; Qing Tong, Guo ; Chye Ng, Soon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-89c725602b7e1bb8d41e2d2d6399716d319381aa8916ce1e1ba19fb4e795ca63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Cardiomyocytes</topic><topic>Cell Differentiation - physiology</topic><topic>Cells, Cultured</topic><topic>Coronary heart disease</topic><topic>Heart</topic><topic>Heart Failure - physiopathology</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Myoblasts, Skeletal - metabolism</topic><topic>Myoblasts, Skeletal - transplantation</topic><topic>Myocardial ischemia</topic><topic>Myocarditis. Cardiomyopathies</topic><topic>Myocytes, Cardiac - physiology</topic><topic>Recovery of Function</topic><topic>Skeletal myoblasts</topic><topic>Transcription Factors - physiology</topic><topic>Transdifferentiation</topic><topic>Transplantation</topic><topic>Transplantation, Autologous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Heng, Boon Chin</creatorcontrib><creatorcontrib>Khawaja Haider, Husnain</creatorcontrib><creatorcontrib>Kwang-Wei Sim, Eugene</creatorcontrib><creatorcontrib>Cao, Tong</creatorcontrib><creatorcontrib>Qing Tong, Guo</creatorcontrib><creatorcontrib>Chye Ng, Soon</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Heng, Boon Chin</au><au>Khawaja Haider, Husnain</au><au>Kwang-Wei Sim, Eugene</au><au>Cao, Tong</au><au>Qing Tong, Guo</au><au>Chye Ng, Soon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reprogramming autologous skeletal myoblasts to express cardiomyogenic function. Challenges and possible approaches</atitle><jtitle>International journal of cardiology</jtitle><addtitle>Int J Cardiol</addtitle><date>2005-04-28</date><risdate>2005</risdate><volume>100</volume><issue>3</issue><spage>355</spage><epage>362</epage><pages>355-362</pages><issn>0167-5273</issn><eissn>1874-1754</eissn><coden>IJCDD5</coden><abstract>Cell transplantation therapy is emerging as a promising mode of treatment following myocardial infarction. Of the various cell types that can potentially be used for transplantation, autologous skeletal myoblasts appear particularly attractive, because this would avoid issues of immunogenicity, tumorigenesis, ethics and donor availability. Additionally, skeletal myoblasts display much higher levels of ischemic tolerance and graft survival compared to other cell types. There is some evidence for improvement in heart function with skeletal myoblast transplantation. However, histological analysis revealed that transplanted myoblasts do not transdifferentiate into functional cardiomyocytes in situ. This is evident by the lack of expression of cardiac-specific antigens, and the absence of intercalated disc formation. Instead, there is differentiation into myotubes that are not electromechanically coupled to neighboring cardiomyocytes. This could in turn limit the clinical efficacy of treatment. This review would therefore examine the various challenges faced in attempting to reprogram autologous skeletal myoblast to express cardiomyogenic function, together with the various possible strategies that could be employed to achieve this objective.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>15884190</pmid><doi>10.1016/j.ijcard.2004.06.009</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0167-5273
ispartof International journal of cardiology, 2005-04, Vol.100 (3), p.355-362
issn 0167-5273
1874-1754
language eng
recordid cdi_proquest_miscellaneous_67814672
source Elsevier
subjects Biological and medical sciences
Cardiology. Vascular system
Cardiomyocytes
Cell Differentiation - physiology
Cells, Cultured
Coronary heart disease
Heart
Heart Failure - physiopathology
Humans
Medical sciences
Myoblasts, Skeletal - metabolism
Myoblasts, Skeletal - transplantation
Myocardial ischemia
Myocarditis. Cardiomyopathies
Myocytes, Cardiac - physiology
Recovery of Function
Skeletal myoblasts
Transcription Factors - physiology
Transdifferentiation
Transplantation
Transplantation, Autologous
title Reprogramming autologous skeletal myoblasts to express cardiomyogenic function. Challenges and possible approaches
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T21%3A13%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reprogramming%20autologous%20skeletal%20myoblasts%20to%20express%20cardiomyogenic%20function.%20Challenges%20and%20possible%20approaches&rft.jtitle=International%20journal%20of%20cardiology&rft.au=Heng,%20Boon%20Chin&rft.date=2005-04-28&rft.volume=100&rft.issue=3&rft.spage=355&rft.epage=362&rft.pages=355-362&rft.issn=0167-5273&rft.eissn=1874-1754&rft.coden=IJCDD5&rft_id=info:doi/10.1016/j.ijcard.2004.06.009&rft_dat=%3Cproquest_cross%3E67814672%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c390t-89c725602b7e1bb8d41e2d2d6399716d319381aa8916ce1e1ba19fb4e795ca63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=67814672&rft_id=info:pmid/15884190&rfr_iscdi=true